Elevance Health Inc.

(New York Stock Exchange)
Back to all articles
Bullish +55

Elevance Health stock weighs a raised EPS outlook

Guidance raised AI-generated analysis

πŸ“ˆ Elevance Health raised its full-year 2026 adjusted EPS guidance to at least $27.00 per share following a strong Q2 performance.

πŸ’° The company reported Q2 EPS of $7.45, beating analyst consensus estimates of $6.21 by $1.24.

πŸ“Š Q2 operating revenue reached $49.8 billion, representing a 0.8% year-over-year increase.

πŸ’΅ Elevance Health generated $1.9 billion in second-quarter operating cash flow.

πŸ₯ Medicare Advantage performance improved after the company executed specific portfolio actions.

⚠️ Medicaid segment remains under pressure from elevated utilization, resulting in a negative 1.75% operating margin outlook for Q2.

πŸ“‰ Stock price was $396.09 on September 25, 2026, trading 9.20% below its 52-week high of $436.24.

πŸš€ The company projects at least 12% adjusted EPS growth for the fiscal year 2027.

πŸ” Investors are evaluating whether Carelon expansion can offset persistent Medicaid cost pressures.

Bullish Signals
  • Elevance Health raised its full-year 2026 adjusted EPS guidance to at least $27.00, signaling confidence in earnings growth.
  • The company delivered a Q2 EPS beat of $1.24 per share, reporting $7.45 against consensus estimates of $6.21.
  • Operating revenue grew 0.8% year-over-year to reach $49.8 billion in the second quarter.
  • Elevance Health generated strong liquidity with $1.9 billion in operating cash flow during Q2 2026.
  • Medicare Advantage performance has improved following strategic portfolio actions taken by management.
Risk Factors
  • Medicaid segment faces persistent cost pressure from elevated utilization, leading to a negative 1.75% operating margin outlook for Q2.
  • The company's stock price traded 9.20% below its 52-week high of $436.24 as of September 25, 2026.
Full Analysis
Elevance Health raised its full-year 2026 adjusted earnings per share (EPS) guidance to at least $27.00 following a strong second quarter performance. The company reported Q2 EPS of $7.45, significantly beating analyst consensus estimates of $6.21. This positive momentum was driven by improved operating revenue of $49.8 billion and robust cash flow generation of $1.9 billion in the quarter. The stock price stood at $396.09 on September 25, 2026, trading below its 52-week high but reflecting investor interest in the company's strategic outlook. While Medicare Advantage performance has improved following recent portfolio actions, the company faces ongoing pressure from Medicaid costs due to elevated utilization rates, which impacted the operating margin outlook for that segment. Looking ahead, Elevance Health projects at least 12% adjusted EPS growth for 2027, contingent on successful execution across its diverse business lines. The central challenge for investors remains whether the gains in Medicare Advantage and expansion of Carelon can sufficiently offset persistent cost pressures within the Medicaid portfolio to sustain long-term profitability.